Navigation Links
Vermillion Reports Financial Results for the First Quarter 2011
Date:5/10/2011

million.  On February 18, 2011, we completed a sale of 4,000,000 shares of our common stock in an underwritten follow-on public offering at a price of $5.45 per share.  Net proceeds of the offering were approximately $20.2 million. The Company utilized $3.4 million in cash and cash equivalents during the first quarter and expects $4-$5 million cash utilization during the second quarter.

Total operating expenses increased in the first quarter of 2011 to $4.8 million from $3.1 million in the same period last year.  These increases were primarily due to the addition of personnel subsequent to the Company's emergence from Chapter 11 bankruptcy protection, investments in sales and marketing to establish the adoption of and reimbursement for OVA1, as well as an increase in clinical trial and collaboration costs for the ongoing development of the Company's ovarian cancer program and PAD blood test, VASCLIR™.  The Company had 25 employees at March 31, 2011 compared to 10 employees at March 31, 2010.  Operating expenses included $1.3 million and $0.9 million in non-cash stock-based compensation expense in the three months ended March 31, 2011 and 2010, respectively.

Net loss for the first quarter of 2011 decreased to $4.3 million, or $0.34 per share, compared to $11.6 million, or $1.14 per share, for the same period in 2010.  Other income and expense for the three months ended March 31, 2010 included $8.3 million in reorganization items.

About VermillionVermillion, Inc. is dedicated to the development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at www.vermillion.com.


'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vermillion Receives Award From the Society of Gynecologic Oncologists
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
5. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
6. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
7. Vermillion Announces the Reappointment of Officers and Confirmation of Director
8. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
9. Vermillion Announces $43.05 Million Private Placement of Common Stock
10. Vermillion Files Plan of Reorganization
11. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... LAKE, N.J. , May 10 Par Pharmaceutical ... its partner, Glenmark Generics Limited and Glenmark Generics Inc., ... & Co. Inc. that resolves patent litigation related to Glenmark,s ... ends the lawsuit involving a challenge by Glenmark which sought ...
... , May 10 /PRNewswire-Asia/ -- On April ... cases with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; ... by the,China International Economic and Trade Arbitration Commission (CIETAC), which,has ...
Cached Medicine Technology:Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2
(Date:8/30/2014)... Colorado Springs, CO (PRWEB) August 30, 2014 ... valuable, and increasingly difficult to get. Snoring and sleep apnea ... breathing stops) rob people and their bed partners of the ... Up to 45% of the population snores and 20 million ... these, only 10% have been diagnosed and treated; and of ...
(Date:8/30/2014)... "My wife suffered neck, back and ... said one of two inventors from Bethel, Alaska. "The ... and neck area. She tried other pillows to little ... assisting in comfort and providing extra sleep." , They ... support the head, neck and back comfortably. This enables ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Market ... Industry, 2009-2019 is a professional and in-depth market ... The report firstly reviews the basic information of ... technology. The report then explores global and China’s ... specification, capacity, production value, and market share etc. ...
(Date:8/30/2014)... 30, 2014 Serving contented clients since ... Profit By Outsourcing is now offering discount for ... company gives emphasize on putting forward the best of ... clients. Their dedicated team of professionals and web developers ... can handle even the critical issues of web development ...
(Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3
... firm announced this week that it has developed a ... improve// the efficacy of chemotherapy drugs and reduce drug ... the US subsidiary of Nitto Denko Corporation, says its ... biocompatible polymer material which can be loaded with therapeutic ...
... study appearing in the Journal of Clinical Oncology reveals ... the lives of patients// with recurrent prostate cancer. ... targeted drugs that scientists at Cedars-Sinai Medical Center in ... in some prostate cancer patients with no previous chemotherapy ...
... of the Medgadget "Most Sci-Fi Sounding Company Name" Award, ... Andara OFS nerve growth stimulation system. ,According ... battery-powered device about the size of a cardiac pacemaker ... attached to the vertebrae at a distance of two ...
... have cautioned about the risk of mercury in canned albacore ... regarding the consumption of tuna in women and children. This ... 8 out of 60 cans of albacore tuna tested contained ... this guideline, four servings of canned albacore tuna per week ...
... A research team has identified certain chemical marks that help ... cells in liposuctioned fat, are best at regenerating// tissue. ... body fat to improve their looks. But unwanted fat also ... heal injuries in the body. ,Uncovering the nature ...
... Medicine have succeeded in producing neurons in vitro ... This is the first time// such an advanced ... from human skin, according to lead researcher Professor ... revolutionary advances in the treatment of neurodegenerative illnesses ...
Cached Medicine News:Health News:New Cost-cutting Cancer Drug Delivery System 2Health News:New Cost-cutting Cancer Drug Delivery System 3Health News:Stem Cells in Liposuctioned Fat can Heal Injuries 2Health News:Scientists Produce Neurons from Human Skin 2